Table 1 Study characteristics
Name of the first author | Year of publication | Study design | Population | Type of RCC | Reference test | No. of Patients analysed | Male, No. (%) | Age (SD or IQR) | Modalities | Image analysis | Tracers |
|---|---|---|---|---|---|---|---|---|---|---|---|
Adams | 2019 | Prospective | Suspected or known RCC | Primary | Histopathology | 27 | 70 | 61 (14) | MRI | Quantitative | – |
Aide | 2003 | Prospective | Suspected RCC | Primary | Histopathology | 35 | 60 | 60 (14) | PET | Qualitative | 18F-FDG |
Alongi | 2016 | Prospective | Suspected or known RCC | Primary | Histopathology and/or other imaging | 104 | 69 | 63 (13) | PET/CT | Qualitative | 18F-FDG |
Aslan | 2018 | Retrospective | Known RCC | Primary | Histopathology | 49 | 52 | 62 (14) | MRI | Qualitative | – |
Bertagna | 2013 | Retrospective | Known RCC | Primary | Histopathology | 68 | 72 | 68 (4) | PET/CT | Qualitative | 18F-FDG |
Chang | 2003 | Retrospective | Known RCC | Primary | Histopathology | 15 | 47 | 56 (15) | PET | Qualitative | 18F-FDG |
Chen | 2014 | Retrospective | Suspected RCC | Primary | Histopathology | 35 | 57 | 57 (29–77) | MRI | Qualitative | – |
Chen | 2015 | Prospective | Suspected RCC | Primary | Histopathology | 71 | 75 | 50 (21–78) | MRI | Qualitative | – |
Choi | 2021 | Retrospective | Known RCC | Primary | Histopathology | 110 | 67 | NR | MRI | Qualitative | – |
Dilhuydy | 2006 | Retrospective | Suspected or known RCC | Recurrent or metastatic | Histopathology | 18 | NR | 57 (13) | PET/CT | Qualitative | 18F-FDG |
Ding | 2016 | Retrospective | Suspected or known RCC | Primary | Histopathology | 35 | 58 | 52 (12) | MRI | Qualitative | – |
Divgi | 2013 | Prospective | Suspected or known RCC | Primary | Histopathology | 204 | 63 | 56 (12) | PET/CT | Qualitative | 124I-girentuximab |
Fisher | 2008 | Prospective | Suspected or known RCC | Primary | Histopathology | 122 | 64 | 58 (32–80) | SPECT | Qualitative | 99mTc-EC20 |
Fuccio | 2014 | Retrospective | Known RCC | Primary | Histopathology | 69 | NR | 62 (36–86) | PET/CT | Qualitative | 18F-FDG |
Goldberg | 1997 | Prospective | Suspected or known RCC | Primary | Histopathology | 10 | 57 | 49 (37–76) | PET | Qualitative | 18F-FDG |
Jadvar | 2003 | Retrospective | Suspected or known RCC | Primary | Histopathology and clinical follow-up | 25 | 72 | NR | PET | Qualitative | 18F-FDG |
Johnson | 2019 | Retrospective | Suspected or known RCC | Primary | Histopathology | 57 | NR | 62 (15) | MRI | Qualitative | – |
Kang | 2004 | Prospective | Suspected or known RCC | Primary | Histopathology | 17 | 74 | 59 (28–79) | PET | Qualitative | 18F-FDG |
Kumar | 2010 | Retrospective | Known RCC | Primary | Histopathology and clinical follow-up and conventional imaging finding | 103 | 87 | 57 (12) | PET/CT | Qualitative | 18F-FDG |
Kwon | 2015 | Prospective | Suspected or known RCC | Primary | Histopathology and clinical follow-up | 73 | 60 | 52 (28–71) | MRI | Qualitative | – |
Li | 2020 | Retrospective | Known RCC | Primary | Histopathology | 127 | 78 | 56 (12) | MRI | Quantitative | – |
Lima | 2020 | Retrospective | Known RCC | Primary | Histopathology | 47 | 55 | 61 (12) | MRI | Qualitative | – |
Lyu | 2018 | Retrospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 35 | 54 | 55 (15) | MRI | Qualitative | – |
Majhail | 2003 | Retrospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 36 | 79 | 63 (45–82) | PET | Qualitative | 18F-FDG |
Miyakita | 2002 | Retrospective | Known RCC | Primary | Histopathology | 19 | 79 | 57 (10) | PET | Qualitative | 18F-FDG |
Muselaers | 2013 | Retrospective | Suspected RCC | Primary | Histopathology | 29 | 41 | 64 (8) | SPECT | Qualitative | 111In-Girentuximab |
Nakamoto | 2019 | Retrospective | Suspected or known recurrent RCC | Primary | Histopathology | 25 | 76 | 64 (38–86) | PET/CT | Qualitative | 68Ga-DOTATOC/18F-FDG |
Nakatani | 2011 | Retrospective | Suspected recurrent RCC | Primary | Histopathology and clinical follow-up | 28 | 75 | 63 (45–78) | PET | Qualitative | 18F-FDG |
Oyama | 2014 | Prospective | Suspected RCC | Primary | Histopathology | 34 | NR | 67 (38–87) | PET | Qualitative | 18F-FDG/11C-acetate |
Ozturk | 2016 | Retrospective | Suspected recurrent or metastatic lesions | Recurrent or metastatic | Histopathology or clinical follow-up | 132 | 68 | 61 (12) | PET | Qualitative | 18F-FDG |
Ozulker | 2011 | Prospective | Suspected RCC | Primary | Histopathology | 18 | 44 | 57 (11) | PET/CT | Qualitative | 18F-FDG |
Park | 2009 | Retrospective | Suspected recurrent or metastatic lesions | Recurrent or metastatic | Histopathology or by clinical follow-up | 63 | 75 | 54 (31–76) | PET/CT | Qualitative | 18F-FDG |
Purkayastha | 2020 | Retrospective | Known RCC | Primary | Histopathology | 43 | 82 | 64 (38–85) | MRI | Quantitative | – |
Ramdave | 2001 | Prospective | Suspected or known primary RCC | Primary | Histopathology | 17 | 56 | 61 (32–79) | PET | Qualitative | 18F-FDG |
Safaei | 2002 | Prospective | Suspected RCC | Primary | Histopathology | 36 | 78 | 54 (11) | PET | Qualitative | 18F-FDG |
Sharma | 2014 | Prospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 16 | 75 | 53 (14) | PET/CT | Qualitative | 18F-Fluoride |
Sheikhbahaei | 2017 | Prospective | Suspected RCC | Primary | Histopathology | 48 | 73 | 59 (40–81) | SPECT/CT | Qualitative | 99mTc-MIBI |
Sistani | 2020 | Prospective | Known RCC | Primary | Histopathology | 31 | 79 | 60 (30–83) | SPECT/CT | Qualitative | 99mTc-MIBI |
Sohaib | 2009 | Prospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 47 | 70 | 62 (29–79) | SPECT/MRI | Qualitative | 99mTc-MDP |
Sun | 2020 | Retrospective | Known RCC | Primary | Histopathology | 45 | 60 | 57 (12) | MRI | Quantitative | – |
Win | 2015 | Retrospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 315 | 85 | 47.5 | PET/CT | Qualitative | 18F-FDG |
Wu | 2002 | Prospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 52 | 67 | (46–73) | SPECT/PET | Qualitative | 99mTc-MDP/18F-FDG |
Youssef | 2018 | Prospective | Suspected metastatic RCC | Recurrent or metastatic | Histopathology | 20 | 65 | NR | PET/CT | Qualitative | 18F-FDG |
Zhao | 2020 | Retrospective | Known RCC | Primary | Histopathology | 35 | 69 | 61 | MRI | Quantitative | – |